C1 total dose
1.8 mg/m²
0.8 + 0.5 + 0.5 (D1/8/15)
Phase 1
Identify what you're billing
Boxed warning, CD22 testing, and the 0.1 mg unit basis are the three things to lock down first.
Boxed Warning — hepatotoxicity / VOD/SOS & post-HSCT mortality FDA label verified May 2026
Two-part Boxed Warning. Both elements drive site-of-care decisions, monitoring frequency, and PA documentation.
Boxed Warning — Hepatotoxicity, including hepatic veno-occlusive disease (VOD), also known
as sinusoidal obstruction syndrome (SOS). VOD/SOS, including severe and sometimes fatal events,
has occurred in patients with relapsed or refractory ALL who received Besponsa. The risk of VOD/SOS was
greater in patients who underwent hematopoietic stem cell transplantation (HSCT) after Besponsa, and in
patients with prior HSCT, ongoing or prior hepatic disease, prior receipt of hepatotoxic chemotherapy,
and greater number of Besponsa treatment cycles. Monitor LFTs at baseline and before each dose. Permanently
discontinue Besponsa if VOD/SOS occurs.
Boxed Warning — Increased risk of post-HSCT non-relapse mortality. Higher non-relapse
mortality was reported in patients receiving Besponsa than in patients receiving standard chemotherapy in
a randomized trial, with the most common causes being VOD/SOS and infection.
Practical implications for billing & site-of-care
- LFT monitoring: baseline + before each dose (Days 1, 8, 15 of every cycle). LFTs include AST, ALT, total bilirubin, alkaline phosphatase.
- Cycle limits: for patients proceeding to allo-HSCT, NCCN recommends limiting Besponsa to ≤2 cycles before transplant to mitigate VOD risk. Maximum 6 cycles total.
- Site of care: typically inpatient or comprehensive cancer center setting due to hepatotoxicity monitoring + complex cycle schedule + R/R B-ALL acuity.
- Other significant W&P: myelosuppression (severe — neutropenia, thrombocytopenia common), tumor lysis syndrome (premedication + monitoring), QT prolongation (baseline + on-treatment ECG/electrolyte monitoring), infusion reactions, embryo-fetal toxicity.
CD22 biomarker — required for prior auth UHC/Aetna/BCBS verified May 2026
CD22 IHC confirmation of CD22+ B-cell precursor ALL is part of the FDA label indication and is required by all major payers in the PA submission.
Besponsa targets CD22, a B-cell-restricted surface antigen expressed on the majority of B-cell ALL blasts. The FDA-approved indication explicitly requires CD22 positivity. There is no FDA-cleared companion diagnostic for CD22 IHC — testing is performed using laboratory-developed test (LDT) IHC at hematopathology labs as part of the standard B-ALL immunophenotyping workup.
| Test | CPT | Notes |
|---|---|---|
| CD22 IHC (initial single antibody, first stain) | 88342 |
Bill once for the first CD22 IHC stain on a specimen |
| CD22 IHC (each additional single antibody) | 88341 |
For multi-antibody panel additions |
| Flow cytometry (alternative or complement) | 88184 + 88185 × addl markers |
Most B-ALL workups use flow + IHC together |
| Bone marrow biopsy (for IHC) | 38221 (BM bx) + 38220 (aspiration) per encounter |
Performed at diagnosis and at relapse staging |
Common PA error: submitting Besponsa PA without explicit CD22+ documentation. Even if
the patient has documented B-ALL, payers want the CD22 IHC report (or flow cytometry CD22 expression
result) attached to the PA. Schedule and resolve CD22 testing BEFORE submitting the Besponsa PA.
ADC class comparison — Besponsa vs sister calicheamicin & MMAE peers Reviewed May 2026
Toxicity profile and billing setup vary by payload chemistry — not by antibody target.
Antibody-drug conjugates (ADCs) combine a monoclonal antibody (target-specific) with a cytotoxic payload (delivers the kill). Toxicity profile is dominated by the payload, not the antibody. Besponsa shares its calicheamicin payload with Pfizer's Mylotarg (gemtuzumab ozogamicin) for AML — both carry the calicheamicin-class hepatic VOD/SOS risk. MMAE-payload ADCs (Adcetris, Polivy, Padcev) carry peripheral neuropathy as the dose-limiting toxicity instead.
| ADC (brand) | HCPCS | Antibody target | Payload class | Class toxicity | Indication |
|---|---|---|---|---|---|
| Besponsa | J9229 |
CD22 | Calicheamicin | VOD/SOS, hepatotoxicity | R/R B-cell precursor ALL |
| Mylotarg (gemtuzumab ozogamicin) | J9203 |
CD33 | Calicheamicin | VOD/SOS, hepatotoxicity | CD33+ AML |
| Adcetris (brentuximab vedotin) | J9042 |
CD30 | MMAE | Peripheral neuropathy, PML | cHL, sALCL, PTCL, CTCL |
| Polivy (polatuzumab vedotin) | J9309 |
CD79b | MMAE | Peripheral neuropathy | 1L & R/R DLBCL |
| Padcev (enfortumab vedotin) | J9177 |
Nectin-4 | MMAE | Skin reactions, peripheral neuropathy | Urothelial carcinoma |
| Enhertu (trastuzumab deruxtecan) | J9358 |
HER2 | Deruxtecan (DXd) | Interstitial lung disease | HER2+/HER2-low solid tumors |
| Trodelvy (sacituzumab govitecan) | J9317 |
Trop-2 | Govitecan (SN-38) | Severe neutropenia, diarrhea | TNBC, urothelial |
Calicheamicin payload → class-specific VOD/SOS risk. Besponsa and Mylotarg are the
two FDA-approved calicheamicin ADCs and they share a payload-driven hepatotoxicity / sinusoidal obstruction
risk profile. This drives the Boxed Warning, the LFT monitoring schedule, the cycle limits before allo-HSCT,
and the inpatient site-of-care preference. MMAE peers (Adcetris, Polivy, Padcev) do NOT carry equivalent
VOD risk — their dose-limiting toxicity is peripheral neuropathy.
Cycle dosing & unit math FDA label verified May 2026
From the FDA prescribing information for Besponsa (BLA 761040, current revision).
Cycle 1 (all patients, 21-day cycle)
- Total cycle dose: 1.8 mg/m²
- Day 1: 0.8 mg/m² IV over 1 hour
- Day 8: 0.5 mg/m² IV over 1 hour
- Day 15: 0.5 mg/m² IV over 1 hour
- Cycle length: 3 weeks (21 days)
Cycles 2 and beyond
If patient achieved CR or CRi (cycle length: 28 days):
- Total cycle dose: 1.5 mg/m²
- Day 1, 8, 15: 0.5 mg/m² each (3 doses × 0.5)
If patient did NOT achieve CR or CRi (cycle length: 28 days):
- Total cycle dose: 1.8 mg/m² (same schedule as Cycle 1)
- Day 1: 0.8 mg/m²; Day 8: 0.5 mg/m²; Day 15: 0.5 mg/m²
Maximum 6 cycles total. NCCN and the FDA label recommend limiting Besponsa to ≤2 cycles
before allo-HSCT in patients proceeding to transplant, to mitigate VOD/SOS risk. Hold/reduce doses per LFTs
and counts. Permanently discontinue if VOD/SOS occurs.
Premedication required before each dose
- Corticosteroid (e.g., dexamethasone)
- Antipyretic (acetaminophen)
- Antihistamine (diphenhydramine)
- Consider cytoreduction with hydroxyurea if circulating lymphoblasts ≥10,000/µL (TLS prevention)
Unit math — the 0.1 mg trap
HCPCS J9229 descriptor: "Inj inotuzumab ozogam 0.1 mg". One billable unit = 0.1 mg, not 1 mg. Convert dose to units by dividing milligrams by 0.1 (i.e., multiply by 10). A 1.5 mg dose = 15 units. A 0.9 mg dose = 9 units. A 1.44 mg dose = 14.4 units.
| BSA (m²) | 0.5 mg/m² dose | Units | 0.8 mg/m² dose | Units | Vials needed |
|---|---|---|---|---|---|
| 1.4 | 0.70 mg | 7.0 u | 1.12 mg | 11.2 u | 1 / 2 |
| 1.6 | 0.80 mg | 8.0 u | 1.28 mg | 12.8 u | 1 / 2 |
| 1.8 | 0.90 mg | 9.0 u | 1.44 mg | 14.4 u | 1 / 2 |
| 2.0 | 1.00 mg | 10.0 u | 1.60 mg | 16.0 u | 2 / 2 |
| 2.2 | 1.10 mg | 11.0 u | 1.76 mg | 17.6 u | 2 / 2 |
Worked example — Cycle 1 Day 1, BSA 1.8 m²
# Calculate dose
Dose = 0.8 mg/m² × 1.8 m² = 1.44 mg
Units = 1.44 / 0.1 = 14.4 units (J9229)
# Vial draw and waste
Vials needed: 2 × 0.9 mg = 1.8 mg drawn
Administered: 1.44 mg (14.4 units)
Waste: 1.8 - 1.44 = 0.36 mg = 3.6 units (JW)
# Claim lines
Line 1: J9229 × 14.4 + JZ (administered)
Line 2: J9229 × 3.6 + JW (discarded)
Admin: 96413 (1-hr chemo IV)
Premeds: 96372
# Reimbursement (Q2 2026 ASP+6%)
Drug administered: 14.4 × $2,816.767 = ~$40,561
Drug waste (JW reimbursable): 3.6 × $2,816.767 = ~$10,140
Total drug per dose: ~$50,702
Cycle 1 total (3 doses): ~$140K (drug only, before sequestration)
Dose = 0.8 mg/m² × 1.8 m² = 1.44 mg
Units = 1.44 / 0.1 = 14.4 units (J9229)
# Vial draw and waste
Vials needed: 2 × 0.9 mg = 1.8 mg drawn
Administered: 1.44 mg (14.4 units)
Waste: 1.8 - 1.44 = 0.36 mg = 3.6 units (JW)
# Claim lines
Line 1: J9229 × 14.4 + JZ (administered)
Line 2: J9229 × 3.6 + JW (discarded)
Admin: 96413 (1-hr chemo IV)
Premeds: 96372
# Reimbursement (Q2 2026 ASP+6%)
Drug administered: 14.4 × $2,816.767 = ~$40,561
Drug waste (JW reimbursable): 3.6 × $2,816.767 = ~$10,140
Total drug per dose: ~$50,702
Cycle 1 total (3 doses): ~$140K (drug only, before sequestration)
NDC reference FDA NDC Directory verified May 2026
| NDC (10/11-digit) | Package | Use |
|---|---|---|
0008-0100-01 / 00008-0100-01 |
0.9 mg lyophilized single-dose vial — 1 vial per carton | All adult R/R B-ALL dosing |
Use the carton-level NDC on the claim form (24A shaded area). N4 qualifier + 11-digit
NDC + UoM (ML) + total volume drawn. Vial-level NDC will trigger denial. The 0.9 mg vial reconstitutes
with 4 mL Sterile Water for Injection to a 0.25 mg/mL final concentration.
Storage and handling: Refrigerate vials at 2°C–8°C in original carton (protect
from light). Reconstituted solution: use immediately or refrigerate up to 4 hours. Diluted solution: use
immediately or refrigerate up to 4 hours; total time from reconstitution to end of administration must
not exceed 8 hours.
Phase 2
Code the claim
JZ + JW required on virtually every claim. The 0.1 mg unit basis is the most common error.
Administration codes CPT verified May 2026
Besponsa is an antibody-drug conjugate (calicheamicin payload) and bills as chemo admin.
| Code | Description | When to use |
|---|---|---|
96413 |
Chemotherapy administration, IV infusion technique; up to 1 hour, single or initial substance/drug | Primary code for Besponsa. 1-hour standard infusion fits within window. Bill once per dose (D1, D8, D15). |
96415 |
Chemotherapy administration, IV infusion; each additional hour | Rarely needed — standard Besponsa infusion is exactly 1 hour. |
96365 / 96366 |
Therapeutic IV infusion (non-chemo) | NOT appropriate. ADCs (calicheamicin payload) bill under chemo admin codes per CPT classification. |
96372 |
Therapeutic SC/IM injection | For premedications (corticosteroid, antipyretic, antihistamine) before each Besponsa dose. |
Why chemo admin for an ADC: CPT chemotherapy administration codes (96409–96425) apply
to complex antibody-drug conjugate administration regardless of mechanism of action. Besponsa carries a
cytotoxic calicheamicin payload and is billed under chemo admin codes per AMA classification. This pays
materially more than 96365 therapeutic infusion.
Modifiers CMS verified May 2026
JZ + JW — both required on virtually every claim
Effective July 1, 2023, CMS requires either JZ (no waste) or JW (waste) on every single-dose container claim. For Besponsa, the 0.9 mg fixed-size vial paired with BSA-based dosing (0.5 or 0.8 mg/m²) produces partial-vial waste on virtually every adult dose.
- Line 1 (administered): J9229 × administered units + JZ
- Line 2 (discarded): J9229 × wasted units + JW (separate claim line)
- JW units are reimbursable but must be reported separately
Common error: Forgetting to bill the JW waste line. CMS audits often catch this. Wasted
drug for Besponsa is reimbursable but must be reported on a separate claim line. Example (BSA 1.8, 0.8 mg/m²):
14.4 units administered (JZ) + 3.6 units discarded (JW) on two separate lines.
Modifier 25 — same-day E/M
Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the infusion (e.g., LFT review and dose-decision encounter before each Besponsa dose). Routine pre-infusion clinical assessment is bundled.
340B modifiers (JG, TB)
For 340B-acquired Besponsa, follow your MAC's current 340B modifier policy. Pfizer Oncology Together's billing materials do not provide 340B-specific instructions.
ICD-10-CM — B-cell precursor ALL FY2026 verified May 2026
Use the most specific ALL code supported by current disease state. Pre-treatment, primary code is typically C91.00 or C91.02 (relapse); maintenance/CR phase uses C91.01.
| Code | Description | When to use |
|---|---|---|
C91.00 | Acute lymphoblastic leukemia not having achieved remission | Most common Besponsa primary. Pre-treatment R/R B-ALL. |
C91.01 | Acute lymphoblastic leukemia, in remission | Post-CR/CRi maintenance phase if continuing Besponsa per protocol. |
C91.02 | Acute lymphoblastic leukemia, in relapse | Documented relapse after prior remission. |
Z51.11 | Encounter for antineoplastic chemotherapy | Required on the admin line. |
Z85.6 | Personal history of leukemia | Post-treatment surveillance encounters. |
D70.1 | Agranulocytosis secondary to cancer chemotherapy | Supplementary if neutropenia documented (Besponsa class effect). |
D69.59 | Other secondary thrombocytopenia | Supplementary if treatment-related thrombocytopenia documented. |
K76.5 | Hepatic veno-occlusive disease | If VOD/SOS develops on therapy (triggers d/c per Boxed Warning). |
E88.3 | Tumor lysis syndrome | Supplementary if TLS documented (premed/cytoreduction failure). |
PA documentation goes beyond ICD-10. All major payers require: (1) C91.0x ICD-10 + B-cell
precursor lineage documented, (2) CD22 IHC positive, (3) prior multi-agent chemotherapy regimen documented
(relapse or refractory status), (4) proposed cycle plan with intent (bridge to allo-HSCT vs continued
therapy), (5) baseline LFTs documented.
Site of care & place of service Verified May 2026
Unlike most chemotherapy infusion drugs, Besponsa is generally administered in inpatient or comprehensive cancer center settings rather than community oncology offices. The combination of R/R B-ALL acuity, hepatotoxicity monitoring (LFTs every dose), VOD/SOS risk, TLS premedication needs, and the typical bridge-to-HSCT pathway all push Besponsa into hospital-based or academic infusion settings.
| Setting | POS | Claim form | Payer steering |
|---|---|---|---|
| Inpatient hospital | 21 | UB-04 / 837I | Common for Cycle 1, especially with TLS risk |
| Hospital outpatient (on-campus) | 22 | UB-04 / 837I | Common for cycles 2–6 if outpatient feasible |
| Hospital outpatient (off-campus PBD) | 19 | UB-04 / 837I | Acceptable for stable patients |
| Comprehensive cancer center / academic infusion | 22 (HOPD) or 11 | per setting | Preferred site for R/R B-ALL |
| Physician oncology office | 11 | CMS-1500 / 837P | Less common — only highly-resourced practices with LFT/ECG monitoring |
| Patient home | 12 | CMS-1500 (with home infusion) | NOT appropriate for Besponsa |
Site-of-care considerations: commercial UM programs that ordinarily steer infusions out
of HOPD typically make exceptions for R/R ALL patients on Besponsa given the hepatotoxicity monitoring
requirements. Document VOD/SOS risk monitoring in the PA narrative when HOPD is the planned site.
Claim form field mapping Pfizer Oncology Together 2026
From Pfizer Oncology Together Codes & Coverage 2026 reference materials.
| Information | CMS-1500 box | Notes |
|---|---|---|
| NPI | 17b | Rendering provider |
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | N4 + 00008-0100-01 + ML + total volume drawn (4 mL per 0.9 mg vial reconstituted) |
| HCPCS J9229 + JZ (administered units) | 24D (drug line 1) | Administered units in 0.1 mg increments |
| HCPCS J9229 + JW (waste units) | 24D (drug line 2) | Discarded units in 0.1 mg increments — separate line, required since 7/1/2023 |
| Drug units | 24G | Administered or wasted units (NOT mg) — multiply mg by 10 |
| CPT 96413 (admin line) | 24D (admin line) | 1-hr chemo IV. Bill once per dose (D1/8/15). |
| CPT 96372 (premed line) | 24D | Premedications: corticosteroid + antipyretic + antihistamine |
| ICD-10 (primary) | 21 | C91.00 (R/R), C91.02 (relapse), or C91.01 (CR/CRi maintenance) |
| CD22 IHC test claim line (separate) | 24D | CPT 88341 / 88342 — typically billed at diagnostic workup encounter |
| PA number | 23 | Required by all major payers |
Sanity check the units field. A correctly billed Besponsa claim for a typical adult will
have units in the 5–18 range per drug line (administered + waste). If you see units of "1" or "2"
for a 1+ mg dose, the biller has confused 1 mg-per-unit with the correct 0.1 mg-per-unit basis. Catch
this before submission — recovery on a denied/under-billed claim is operationally expensive.
Phase 3
Get paid
CD22 documentation + LFT baseline + prior multi-agent regimen documentation are PA cornerstones.
Payer policy snapshot Reviewed May 2026
All major payers require PA, CD22 documentation, and prior multi-agent chemotherapy documentation. NCCN Cat 1 in R/R B-ALL bridge to allo-HSCT.
| Payer | PA? | Documentation focus | Site-of-care UM |
|---|---|---|---|
| UnitedHealthcare Oncology Med Coverage Policy |
Yes | R/R CD22+ B-cell precursor ALL + CD22 IHC + prior ≥1 multi-agent regimen + intent (bridge-to-HSCT preferred) | Generally accepts HOPD for Besponsa given hepatotoxicity monitoring |
| Aetna CPB + Medical Drug policies |
Yes | NCCN-aligned R/R B-ALL; CD22+ confirmation + LFT baseline | HOPD acceptable for Besponsa given monitoring |
| BCBS plans Vary by plan |
Yes | NCCN Cat 1 R/R B-ALL; CD22 IHC + prior multi-agent regimen documented | Plan-specific; HOPD typically accepted |
| Medicare LCDs Per MAC |
Yes | Label indication + NCCN compendium support | Per MAC LCD |
Step therapy
By definition, Besponsa is second-line or later — the FDA indication is for relapsed or refractory CD22+ B-cell precursor ALL, which means at least one prior multi-agent chemotherapy regimen (typically a hyperCVAD, augmented BFM, or pediatric-inspired adult ALL regimen). Document the prior regimen(s), best response, and reason for discontinuation/relapse in the PA.
NCCN designation
NCCN ALL Guidelines list Besponsa as a Category 1 preferred regimen for R/R Ph-negative and Ph-positive B-cell precursor ALL, particularly as a bridge to allogeneic HSCT. Cite the NCCN compendium in PA submissions and appeals.
Medicare reimbursement CMS Q2 2026 (live)
Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.
Q2 2026 payment snapshot — J9229
Effective April 1 – June 30, 2026 · Based on 4Q25 ASP submissions
ASP + 6% (per 0.1 mg unit)
$2,816.767
per billable unit
Per mg equivalent
$28,167.67
per mg (10 units × ASP+6%)
1.44 mg dose (BSA 1.8, 0.8 mg/m²)
$40,561.45
14.4 units × ASP+6% (administered only)
Cycle 1 cost (drug only, BSA 1.8 m²):
Day 1 (1.44 mg = 14.4 units): ~$40,561 + ~$10,140 waste ≈ $50,702 ·
Day 8 (0.9 mg = 9 units): ~$25,351 (no waste, 1 vial) ·
Day 15 (0.9 mg = 9 units): ~$25,351 (no waste, 1 vial). C1 total: ~$101K drug + waste.
Full course (avg 3–4 cycles before HSCT): ~$300K–$400K drug only. Sequestration
(~2%) reduces actual paid to roughly ASP + 4.3%.
Coverage
No NCD specific to inotuzumab ozogamicin. Coverage falls under MAC LCDs for biologics/oncology + the generic drug-coverage framework. All MACs cover J9229 for the FDA-approved label indication (R/R CD22+ B-cell precursor ALL) with appropriate ICD-10 (C91.0x family), CD22 documentation, and prior multi-agent chemotherapy documentation.
Code history
- J9229 — permanent code, "Inj inotuzumab ozogam 0.1 mg." Effective shortly after FDA approval (August 17, 2017, BLA 761040). Pre-permanent-code period used unclassified J9999.
Patient assistance — Pfizer Oncology Together Pfizer verified May 2026
- Pfizer Oncology Together: 1-877-744-5675 / pfizeroncologytogether.com — benefits investigation, prior authorization assistance, appeals support
- Besponsa Co-Pay Card: commercial $0 first dose; eligible commercially-insured patients (excludes Medicare, Medicaid, federal program patients)
- Pfizer Patient Assistance Foundation: free product for uninsured / underinsured patients meeting income requirements (administered through the Pfizer Patient Assistance Foundation, a 501(c)(3))
- Foundations (Medicare): for Medicare patients, refer to PAN, HealthWell, CancerCare, Leukemia & Lymphoma Society (LLS) — verify open leukemia/ALL-specific funds quarterly
- Web: besponsa.com / pfizeroncologytogether.com
Need to model what a specific patient will actually pay after copay assistance, deductible, coinsurance,
and OOP max? Run a CareCost Estimate — J9229 pre-loaded.
Phase 4
Fix problems
The 0.1 mg unit error, missing JW waste line, and missing CD22 documentation are the top three.
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| Drug units severely under-billed | 1 mg-per-unit assumed (J9229 is 0.1 mg-per-unit) | Resubmit corrected units: multiply mg by 10. A 1.44 mg dose = 14.4 units, not 1.4. |
| JW waste line missing | Wasted drug not reported (BSA dosing + 0.9 mg vial) | Add JW line for discarded units. JZ on administered units; JW on wasted units (separate line). Required since 7/1/2023. |
| CD22 not documented in PA | PA submitted without CD22 IHC result | Submit CD22 IHC report. Schedule CD22 testing FIRST (before Besponsa PA). |
| Wrong admin code (96365) | Therapeutic IV billed instead of chemo IV | Resubmit with 96413. Besponsa is chemo admin per CPT classification (calicheamicin payload). |
| Prior therapy not documented | R/R designation challenged without prior regimen documented | Submit prior multi-agent chemotherapy regimen, best response, and date of relapse/progression. |
| Wrong NDC format | Non-carton or wrong NDC submitted | Use 00008-0100-01 with N4 qualifier in 24A shaded area. |
| Site of care challenge | HOPD billed for non-acuity-justified case | Submit medical necessity narrative citing hepatotoxicity monitoring + Boxed Warning + LFT q-dose schedule. |
| VOD/SOS develops on therapy | Continued dosing after VOD signal | Permanently discontinue per Boxed Warning. Document K76.5 if VOD diagnosed. |
| HCPCS confused with Mylotarg J9203 | Sister calicheamicin ADC billed under wrong code | J9229 = inotuzumab ozogamicin (Besponsa, anti-CD22, B-ALL). J9203 = gemtuzumab ozogamicin (Mylotarg, anti-CD33, AML). Different drug, different indication. |
Frequently asked questions
What is the HCPCS code for Besponsa?
Besponsa (inotuzumab ozogamicin IV) is billed under HCPCS J9229 — "Inj inotuzumab
ozogam 0.1 mg." One billable unit equals 0.1 mg, NOT 1 mg. This is the most common
biller error trap on this drug. A 1.5 mg dose = 15 units, not 1.5 units. J9229 has been a permanent
code since shortly after the FDA approval on August 17, 2017 (BLA 761040, the first FDA-approved
CD22-targeted antibody-drug conjugate).
How many units do I bill for a 1.44 mg Besponsa dose?
Bill 14.4 units (1.44 mg ÷ 0.1 mg/unit). For a typical BSA 1.8 m² patient on Cycle 1 Day 1 (0.8 mg/m²), the dose is 1.44 mg. Two 0.9 mg vials are required (1.8 mg total drawn) — bill 14.4 units with JZ on the administered line and 3.6 units with JW on a separate waste line.
What administration CPT do I use for Besponsa?
CPT 96413 — "Chemotherapy administration, IV infusion technique; up to 1 hour, single
or initial substance/drug." Besponsa is an antibody-drug conjugate (calicheamicin payload) and bills as
chemo admin per CPT classification. Standard infusion is 1 hour per dose. 96415 (each additional hour)
is rarely needed. Premedications (corticosteroid, antipyretic, antihistamine) bill under 96372. Do NOT
bill 96365.
Do I bill JZ or JW for Besponsa?
Both, on virtually every adult claim. The 0.9 mg single-dose vial paired with BSA-based dosing produces
partial-vial waste on most doses. Bill JZ for the administered units (line 1) and JW
for the discarded units (line 2, separate line). Required since CMS's July 2023 single-dose container policy.
What is the Medicare reimbursement for J9229?
For Q2 2026, the Medicare Part B payment limit for J9229 is $2,816.767 per 0.1 mg unit (ASP + 6%). On a per-mg basis that equals approximately $28,167.67/mg — among the highest per-mg specialty drug rates in oncology. A typical 1.44 mg Cycle 1 Day 1 dose reimburses at approximately $40,561 (administered) plus the JW waste line. Sequestration (~2%) reduces actual paid to roughly ASP + 4.3%.
What is the Boxed Warning for Besponsa?
Two-part Boxed Warning: (1) Hepatotoxicity, including hepatic veno-occlusive disease / sinusoidal obstruction syndrome (VOD/SOS), which can be severe and sometimes fatal — risk increases with prior or subsequent HSCT; (2) Increased risk of post-HSCT non-relapse mortality. LFT monitoring is required at baseline and before each dose. Many programs limit Besponsa to ≤2 cycles before allo-HSCT to mitigate VOD risk. Site of care is typically inpatient or comprehensive cancer center.
Does Besponsa require CD22 testing for prior auth?
Yes. CD22 immunohistochemistry (IHC) confirmation of CD22-positive B-cell precursor ALL is required by
all major payers (UHC, Aetna, BCBS) and is part of the FDA label indication. Bill CD22 IHC under CPT
88341 or 88342 at the diagnostic workup. CD22 result must be included in the
prior authorization submission alongside dx, prior therapy documentation, and proposed cycle plan.
How does Besponsa compare to other antibody-drug conjugates?
Besponsa (anti-CD22, calicheamicin payload) and Mylotarg (gemtuzumab ozogamicin, J9203, anti-CD33, calicheamicin payload) are sister calicheamicin ADCs — they share the calicheamicin-class hepatic VOD/SOS risk profile. MMAE-payload ADCs (Adcetris J9042 anti-CD30, Polivy J9309 anti-CD79b, Padcev J9177 anti-Nectin-4) carry peripheral neuropathy as the dose-limiting toxicity. Enhertu (J9358, deruxtecan) carries interstitial lung disease risk. Trodelvy (J9317, govitecan) carries severe neutropenia and diarrhea. Toxicity profile is payload-driven, not target-driven.
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- Pfizer Oncology Together — Besponsa Codes & Coverage HCP page
- DailyMed — BESPONSA (inotuzumab ozogamicin) Prescribing Information
- FDA Besponsa label PDF (initial approval, August 2017)
- CMS — Medicare Part B Drug ASP Pricing File
- SEER CanMED — HCPCS J9229 reference
- UnitedHealthcare — Oncology Medication Clinical Coverage Policy
- Aetna Clinical Policy Bulletins — oncology medical drug policies
- NCCN Clinical Practice Guidelines — Acute Lymphoblastic Leukemia (Besponsa Cat 1 in R/R B-ALL)
- FDA — Approval announcement for inotuzumab ozogamicin (August 17, 2017)
- FDA National Drug Code Directory
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP pricing | Quarterly | Auto-bound to CareCost ASP layer; updates on CMS file release. |
| Payer policies (UHC, Aetna, BCBS) | Semi-annual | Manual review against published payer policy documents. |
| HCPCS / CPT / modifier rules | Annual | Reviewed against CMS HCPCS quarterly files and AMA CPT releases. |
| NDC, dosing, FDA label, Boxed Warning | Event-driven | Tied to manufacturer document version + FDA label revision date. |
| NCCN compendium designation | Event-driven | Tied to NCCN ALL Guideline version. |
Reviewer
Pending SME review. This page is staff-authored from primary sources (FDA label, CMS,
Pfizer Oncology Together, NCCN, payer documents — all linked above). Editorial review in progress. Until that review is complete, treat this as a draft reference
and verify each cited source for high-stakes claims.
Change log
- — Initial publication. ASP data: Q2 2026 ($2,816.767 per 0.1 mg unit). Manufacturer source: Pfizer Oncology Together 2026. FDA label: BLA 761040 current revision. NCCN ALL Guidelines (Besponsa Cat 1 R/R B-ALL bridge to allo-HSCT).
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indication and Boxed Warning content is verified against the current FDA label revision. ADC class comparison facts are verified against each comparator's FDA label. We do not paraphrase from billing-software vendor blogs.